---
title: "Clinical-Stage Biotechnology Industry"
description: "264 SEC filers are classified under the Standard Industrial Classification codes that describe the clinical-stage biotechnology industry."
canonical: https://www.getswoopr.com/stocks/industries/health-care/clinical-stage-biotechnology/
source: "Swoopr Investment: https://www.getswoopr.com"
---

# Clinical-Stage Biotechnology Industry

## Direct Answer

264 SEC filers are classified under the Standard Industrial Classification codes that describe the clinical-stage biotechnology industry, and their latest annual reports show $546.7 billion of combined revenue and a median operating margin of -320.5%. Investors should still evaluate its revenue model, industry-specific KPIs, valuation framework and the risks that can change the group's economics.

## Industry Overview

Clinical-stage biotechnology companies develop drug candidates in human trials without approved products and rely on investors and partners for funding. Value depends on trial results, regulatory milestones and cash runway. The first numbers to compare across companies here are trial phase and readout timing, cash and runway and pipeline breadth.

## Key Industry Metrics

- **Trial phase and readout timing**: Which phase each candidate is in and when results are expected. Later phases carry higher value but also decisive risk, and readouts are the main events that move a company's prospects.
- **Cash and runway**: Cash on hand and the months of spending it can fund. Without product sales, this sets how long trials can continue before new financing.
- **Pipeline breadth**: Number of programs and the variety of targets and diseases. A broader pipeline spreads risk, but spreading cash across many programs can slow each.
- **Partnership terms**: Upfront payments, milestones and royalties from deals with larger drugmakers. Terms show how a partner valued the science and how much value the developer retains.
- **Operating spend**: Research, trial and administrative expenses per period. It sets the burn rate, so compare it with cash to see how long operations can continue.

## Primary Macro Drivers

- **Clinical and regulatory milestones**: A positive trial or regulator decision can change a company's value sharply and unlock partners or financing, so these dates matter most.
- **Biotech funding and sector sentiment**: When investors are willing to fund early-stage drugmakers, companies can raise money on better terms and extend runway.
- **Partnerships and acquisitions**: A partnership brings cash and shares costs, while a takeover can end the company's independence and set a price for its pipeline.
- **Scientific advances**: New findings in biology and tools can open new targets and improve trial design, which affects which programs attract funding.

## Major Risks

- **Trial failure**: A failed trial can make a lead program worthless and force cuts, so watch trial phase and expected readout timing.
- **Dilutive financings**: Without product sales, companies fund spending by issuing shares or debt, which dilutes holders; watch cash and runway against operating spend.
- **Regulatory rejection**: A regulator may require more data or refuse approval, which delays or ends a program; watch correspondence with regulators disclosed in filings.
- **Competition**: Other companies working on the same target may finish first or show better data; watch rivals' trial stage and results.

## Industry Characteristics

| Characteristic | Profile |
| --- | --- |
| Cyclicality | Mixed |
| Capital Intensity | Low |
| Regulatory Intensity | High |
| Industry Maturity | Growth |
| Geographic Importance | U.S. / Global |

## Clinical-Stage Biotechnology Filers in the SEC Record

264 companies with annual reports in the dataset are classified by the SEC in the Standard Industrial Classification codes 2836, 2834. Their latest fiscal years end between 2022 and 2026, and together they reported $546.7 billion of revenue. Median revenue growth over the prior year was 11.6%. Median operating margin was -320.5% and median net margin -202.0%. Median total liabilities were 40% of total assets, and 57 of 264 reported a profit in their latest year.

| Company | Revenue | Growth | Operating margin | Net margin | Year |
| --- | --- | --- | --- | --- | --- |
| [Johnson & Johnson](https://www.getswoopr.com/stocks/companies/johnson-and-johnson/) | $94.2 billion | 6.0% | n/a | 28.5% | FY 2025 |
| [Eli Lilly & Co](https://www.getswoopr.com/stocks/companies/eli-lilly/) | $65.2 billion | 44.7% | n/a | 31.7% | FY 2025 |
| [Pfizer Inc](https://www.getswoopr.com/stocks/companies/pfizer/) | $62.6 billion | -1.6% | n/a | 12.4% | FY 2025 |
| [Abbvie Inc.](https://www.getswoopr.com/stocks/companies/abbvie/) | $61.2 billion | 8.6% | 24.6% | 6.9% | FY 2025 |
| [Bristol Myers Squibb Co](https://www.getswoopr.com/stocks/companies/bristol-myers-squibb/) | $48.2 billion | -0.2% | n/a | 14.6% | FY 2025 |
| [Abbott Laboratories](https://www.getswoopr.com/stocks/companies/abbott-laboratories/) | $44.3 billion | 5.7% | 18.2% | 14.7% | FY 2025 |
| [Amgen Inc](https://www.getswoopr.com/stocks/companies/amgen/) | $36.8 billion | 10.0% | 24.7% | 21.0% | FY 2025 |
| [Gilead Sciences, Inc.](https://www.getswoopr.com/stocks/companies/gilead-sciences/) | $29.4 billion | 2.4% | 34.0% | 28.9% | FY 2025 |

The 8 largest of 264 by revenue. Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. A company's SIC code reflects its main business as the SEC records it, so it can differ from how an index provider or analyst classifies the company, and a diversified group appears under only one code.

## Where to Go Next

The Clinical-Stage Biotechnology guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.

### More in Health Care

- [Health Care sector overview](https://www.getswoopr.com/stocks/industries/health-care/)
- [Clinical Trial Technology](https://www.getswoopr.com/stocks/industries/health-care/clinical-trial-technology/)
- [Cell Therapy](https://www.getswoopr.com/stocks/industries/health-care/cell-therapy/)
- [Clinical Workflow Software](https://www.getswoopr.com/stocks/industries/health-care/clinical-workflow-software/)
- [Care Delivery](https://www.getswoopr.com/stocks/industries/health-care/care-delivery/)
- [CNS Pharmaceuticals](https://www.getswoopr.com/stocks/industries/health-care/cns-pharmaceuticals/)
- [Cardiovascular Devices](https://www.getswoopr.com/stocks/industries/health-care/cardiovascular-devices/)
- [Contract Development & Manufacturing Organizations](https://www.getswoopr.com/stocks/industries/health-care/contract-development-and-manufacturing-organizations/)
- [Cardiometabolic Pharmaceuticals](https://www.getswoopr.com/stocks/industries/health-care/cardiometabolic-pharmaceuticals/)

### Put it to work

- [How to analyze a stock](https://www.getswoopr.com/stocks/how-to-analyze-a-stock/)
- [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/)
- [Company research](https://www.getswoopr.com/stocks/companies/)
- [All industries](https://www.getswoopr.com/stocks/industries/)

## Frequently Asked Questions

What are the main KPIs for the Clinical-Stage Biotechnology industry?

Key performance indicators for the Clinical-Stage Biotechnology industry include: Trial phase and readout timing, Cash and runway, Pipeline breadth, Partnership terms, Operating spend. Which matter most depends on the company's model, so compare them across several companies rather than relying on one.

How cyclical is the Clinical-Stage Biotechnology industry?

The Clinical-Stage Biotechnology industry exhibits mixed cyclicality characteristics. Some segments move with the broader economy while others maintain more stable demand, making stock selection within the group particularly important.

What are the biggest risks in the Clinical-Stage Biotechnology industry?

The primary risks for Clinical-Stage Biotechnology companies include: Trial failure, Dilutive financings, Regulatory rejection, Competition. Investors should assess each company's exposure to these factors and its track record of navigating them.

**[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)**

Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).